Ballenberger Freytag Wenisch Institut fuer klinische Forschung GmbH — Clinical Trial Site

9 Registered trials

4 Currently recruiting

Organisation

Ballenberger Freytag Wenisch Institut fuer klinische Forschung GmbH

Location

Neu-Isenburg, Germany

Identifier

ORG-100049022

Address

Robert-Koch-Strasse 1, 63263, Germany

Departments

4502: Internal medicine
Institut für klinische Forschung
N/A
NA
Pneumologie
Studienzentrum

Clinical trials at this site (9)

Search interface

A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting

2025-524580-21-00 Grass pollen induced allergic rhinitis or rhinoconjunct 10 2026-06-01
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti… Recruiting

2024-517991-39-00 Asthma 5 2025-07-22
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Recruiting

2024-515162-13-00 Eosinophilic Asthma 5 2025-04-29
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex… Ended

2024-513462-19-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-30
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28